Despite the increasing number of early‐phase clinical trials focusing on cytokine‐based immunomodulating strategies in cancer treatment,114 some paradoxical effects (for instance, the aforementioned CCL5/CCR5 signalling participates in both NK cell and CAF recruitments) may imply that targeting the cytokine network for immunomodulation still requires ample investigations for understanding their biological functions and potential roles to serve as therapeutic targets. Here, CCL5 is linked to cancer.